Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108519 | 1.00 | IDO1 (0.47) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL28971366 | 1.00 | IDO1 (0.47) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL5852603 | 1.00 | IDO1 (0.47) | IDO1PDPK1CYP11B2RETHTR2A | |
| SCHEMBL9492857 | 0.88 | IDO1 (0.50) | IDO1 | |
| SCHEMBL5852536 | 0.88 | IDO1 (0.50) | IDO1 | |
| SCHEMBL8201616 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL5061699 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL2370159 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL2696782 | 0.77 | KMT2A (0.46) | HTR2A | |
| SCHEMBL18650080 | 0.75 | SRD5A1 (0.43) | IDO1PDPK1CYP11B2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3338813-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-3558399-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-01-14 | — | — | EP | claimed |
| EP-3672615-B1 | FBSA-BASED THERAPEUTIC AND RADIOIMAGING CONJUGATES TARGETING CARBONIC ANHYDRASE POSITIVE CANCERS | PURDUE RESEARCH FOUNDATION (US) | 2025-04-02 | — | — | EP | claimed |
| EP-3842076-B1 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2023-02-15 | — | — | EP | claimed |
| US-20220082003-A1 | TEMPERATURE REACTIVE ACOUSTIC PARTICLES FOR MAPPING FRACTURES | US ENERGY (US) | 2022-03-17 | — | — | US | claimed |
| CN-110087695-B | Multilayer wound care product with perforated release layer | BSN医疗有限公司 | 2022-02-25 | — | — | CN | claimed |
| EP-0853774-B1 | HOLOGRAPHIC MEDIUM AND PROCESS | POLAROID CORP (US) | 2001-11-07 | — | — | EP | claimed |
| EP-0853774-A1 | HOLOGRAPHIC MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1998-07-22 | — | — | EP | claimed |
| US-5759721-A | Holographic medium and process for use thereof | POLAROID CORPORATION (US) | 1998-06-02 | — | — | US | claimed |
| WO-1997013183-A1 | HOLOGRAPHIC MEDIUM AND PROCESS | POLAROID CORPORATION (US) | 1997-04-10 | — | — | WO | claimed |
| EP-3338813-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-04-15 | — | — | EP | disclosed |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3558399-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250368609-A1 | TRIAZINANE COMPOUND AND COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2025-12-04 | — | — | US | disclosed |
| US-4929627-A | ANALGESICS, DIURETICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-05-29 | — | — | US | disclosed |
| US-4876269-A | ANALGESICS, DIURETICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| EP-0260555-A1 | Benzo-fused cycloalkane and oxa- and thia-, cycloalkane trans-1,2-diamine derivatives | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1988-03-23 | — | — | EP | disclosed |
| EP-0163458-A1 | Tetrahydronaphthalenols for the treatment of hypertension | E.R. Squibb & Sons, Inc. (US) | 1985-12-04 | — | — | EP | disclosed |
| US-3953383-A | REACTION PRODUCT OF ORGANOMETALLIC AND S OR ACTIVE HYDROGEN COMPOUND | NIPPON OIL SEAL INDUSTRY CO., LTD. (JA) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508319-B2 | Luteinizing hormone-releasing hormone receptor (LHRH-R) conjugates and uses thereof | LHCGR, GNRHR, SSTR1 | IDO1 882/4885PDPK1 4687/4885CYP11B2 1559/4885 |
| US-20260048157-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP)-TARGETED IMAGING AND THERAPY | FAP, FIBP, FGFR1 | IDO1 547/4885PDPK1 3986/4885CYP11B2 4868/4885 |
| US-20250368609-A1 | TRIAZINANE COMPOUND AND COMPOSITION CONTAINING SAME | WEE1, WEE2, NOTUM | IDO1 644/4885PDPK1 2789/4885CYP11B2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.